Following GMP certification in China, Colombia, Brazil, Argentina, Egypt, Indonesia and Pakistan, Kexing BioPharm, the global licensee for bevacizumab injection in emerging markets, has initiated ...

ISELIN, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ...

Outlook Therapeutics’ second attempt to market an ophthalmic version of Roche’s tried-and-true Avastin in the U.S. has been knocked back by the FDA. In a new complete response letter, the FDA has ...

The FDA's complete response letter highlights insufficient efficacy evidence for bevacizumab-vikj in treating wet AMD, despite previous safety confirmations. NORSE EIGHT study failed its primary ...

The Agency is now requiring the submission of confirmatory efficacy data to support the application. The Food and Drug Administration (FDA) has issued another Complete Response Letter (CRL) to Outlook ...

University of Kentucky Markey Cancer Center researchers have discovered a genetic biomarker that could help identify patients with glioblastoma most likely to benefit from the cancer drug bevacizumab.

Dutch patients with neovascular age-related macular degeneration (AMD) who initiated bevacizumab achieved greater long-term improvements in visual acuity than patients in socioeconomically similar ...

Please provide your email address to receive an email when new articles are posted on . First-line anlotinib plus chemotherapy had noninferior PFS to bevacizumab plus chemotherapy for certain ...

An interaction can occur because one substance causes another substance to have a different effect than expected. Interactions can also occur if you have certain health conditions. Keep reading to ...

High-risk advanced ovarian cancer patients showed marginal survival benefit with bevacizumab added to first-line chemotherapy. Patients without high-risk characteristics did not show significant ...

Pharmacokinetic, safety, efficacy, and immunogenicity data showed Jobevne was similar to the reference product. The approval was supported by a comprehensive clinical package, which included ...